首页 | 本学科首页   官方微博 | 高级检索  
检索        

异甘草酸镁在肝动脉栓塞化疗时保肝作用的临床研究
引用本文:孙正令,武倩,王焕君.异甘草酸镁在肝动脉栓塞化疗时保肝作用的临床研究[J].伤残医学杂志,2014(2):18-20.
作者姓名:孙正令  武倩  王焕君
作者单位:[1]山东省青州荣军医院,山东青州262500 [2]山东省潍坊市益都中心医院,山东青州262500
摘    要:目的:观察异甘草酸镁在肝动脉栓塞化疗( TACE)中的保肝作用。方法:将72例原发性肝癌患者随机分为对照组与治疗组。对照组仅给予肝动脉栓塞化疗和营养支持治疗,治疗组在对照组治疗基础上加用异甘草酸镁(150mg/d)行保肝治疗,连续用药14d。结果:2组治疗后临床症状均明显改善(P>0.05),但在复常天数上有明显差异(P<0.05)。治疗组治疗前、后肝功能指标水平无变化,TACE结束后第3天、7天对照组总胆红素均显著高于治疗组( P <0.01),TACE结束后第14天有所下降,但仍高于治疗组( P <0.05);TACE结束后第3天、7天对照组丙氨酸氨基转移酶和天门冬酸氨基转移酶较治疗组明升高( P <0.01), TACE结束后第14天降至正常;对照组白蛋白与治疗组比较:TACE结束后第7天开始明显下降( P <0.05), TA-CE结束后第14天有所回升,但未至正常水平( P <0.05)。结论:异甘草酸镁可以防止正常肝细胞损害,保护肝功能,增强患者对栓塞化疗的耐受性。

关 键 词:异甘草酸镁  肝功能  原发性肝癌  肝动脉栓塞化疗

Hepatoprotective effect of magnesium isoglycyrrhizinate injection on patientsu ndergoing transcathe ter arterial chemoemblo ization
Institution:SUN Zheng - ling, WANG Huan -jun The Qingzhou Invalides Hospital ShanDong Province ;2625002
Abstract:Objective:To observe the hepatoprotective effect of Magnesium Isoglycyrrhizinate Injection on patients undergoing tran -scatheter arterial chemoembolization ( TACE) .Methods:A total of 46 patients with primary hepatocellular carcinoma ( PHC) were random-ized to trial and control group .The control group received supporting treatment alone from the first TACE day ,while the trial group received Magnesium Isoglycyrrhizinate Injection 150 mg/d in combination with supporting treatment for 10 consecutive days .Results:The symptoms of two groups were significantly improved (P 〉0.05),but the improving days had significant differences (P〈0.05).The trial group showed no significant differences in parameters of liver function before and after receiving TACE On days 3 and 7 after the completion of TACE,the total bilirubin level in control group was significantly higher than in trial group ( P 〈0.01),but slightly reduced on days 14, yet it was still higher than in the trial group ( P 〈0.05) On days 3 and 7 after the completion of TACE ,the ALT and AST levels in the control group ( P 〈0.01) were significantly higher than in the trial group ( P 〈0.01) , but reduced to the normal level on days 14;the ALB level began to decrease significantly from day 7 after the completion of TACE ( P 〈0.05),but rebounded slightly on day 14 , yet it failed to return to the normal level ( P 〈0.05) .Conclusion:Magnesium Isoglycyrrhizinate Injection could prevent hepatocellular damage and protect liver function and enhance patients'tolerance to TACE.
Keywords:Magnesium Isoglycyrrhizinate Injection  Liver function  Primary hepatic carcinoma  Transcatheter hepatic arterial chemoembolization
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号